In a significant shift in the conversation surrounding weight loss and health, a recent study led by Davide Arillotta at the University of Florence, Italy, has shed light on the unexpected behavioral changes associated with GLP-1 medications like Wegovy and Ozempic. These drugs, which mimic the satiety hormone GLP-1, have gained popularity for their effectiveness in curbing appetite and promoting weight loss. However, users have reported a surprising decrease in urges not just for food, but also for alcohol, smoking, and even compulsive shopping.
On March 26, 2025, the findings from the study were highlighted in various discussions, particularly on Reddit's weight-loss forums, where many individuals shared their personal experiences. One user remarked, "I just cannot believe how I don’t crave alcohol anymore!" Another noted, "Took my first shot… have not had a drink or cigarette since." These anecdotes suggest that the impact of GLP-1 drugs may extend beyond mere appetite suppression.
As the conversation surrounding these medications continues to evolve, it raises questions about their potential to address addiction and other compulsive behaviors. According to the study, if these anecdotal reports can be validated through controlled clinical trials, it could lead to new approaches for dealing with addiction by targeting the brain's reward systems. This revelation is particularly significant given the ongoing discussions about the societal implications of weight loss drugs.
The broader cultural context cannot be overlooked. Jessica Cruel, editor in chief of SELF magazine, recently reflected on her personal experiences with diet culture and the shifting ideals surrounding body image. In her editorial, she recounted growing up amidst her mother's endless dieting attempts, which included everything from Weight Watchers to Atkins. She expressed concern that society is slipping back into an era where "thin is in," driven by the popularity of GLP-1 medications.
In 2017, SELF took a bold step by publishing The Weight Issue, aimed at challenging conventional views on weight and health. This was part of a larger cultural shift toward body positivity, which celebrates beauty at all sizes. However, Cruel argues that the rise of GLP-1 drugs has complicated this narrative, leading to a resurgence of unrealistic body ideals. She pointed out that the body positivity movement has struggled to maintain its momentum in the face of these new trends.
With the FDA's approval of Wegovy and Zepbound for weight loss, discussions about these medications have surged, drawing parallels to the public discourse surrounding the COVID vaccine. Cruel emphasized the need for a nuanced conversation about weight loss, acknowledging that while these drugs can be effective, they also come with uncertainties regarding long-term effects.
Reflecting on her own journey, Cruel shared that she gained 40 pounds due to stress-related habits and considered using weight loss shots to regain her health. After losing 25 pounds, she found herself still classified as obese, despite being healthy according to standard medical tests. This experience highlights the flawed nature of the BMI metric, which often fails to capture the complexities of individual health.
In her commitment to fostering a more inclusive conversation around health, Cruel outlined a new direction for SELF. The publication aims to represent diverse body types and perspectives while steering clear of promoting diets. Instead, it will focus on providing information about weight loss drugs without encouraging their use. This decision reflects a broader understanding that health is not solely defined by weight but encompasses movement, nutrition, sleep quality, and mental well-being.
As Cruel stated, "Taking care of your mind and body is hard. Whether you want to lose weight, gain it, or couldn’t care less, SELF will always be here for you, devoid of judgment." This approach emphasizes the importance of supporting readers in their personal health journeys, regardless of their size or weight goals.
In the context of the current medical and social landscape, the implications of GLP-1 drugs extend beyond individual weight loss. They touch on larger themes of addiction, societal pressures, and the evolving understanding of health. As more individuals share their experiences with these medications, it becomes crucial to navigate this conversation with care and empathy.
Ultimately, the intersection of weight loss drugs and body image presents both challenges and opportunities. While the allure of quick fixes may tempt some, the conversation surrounding health must remain grounded in compassion and inclusivity. By acknowledging the complexities of weight and health, publications like SELF can contribute to a more informed and supportive dialogue.
As we move forward, it will be essential to keep the lines of communication open, allowing for diverse voices and experiences to shape the narrative around health and wellness. The journey toward understanding and acceptance is ongoing, and it requires a commitment to listening and learning from one another.
